股本结构
单位：万股
| 公告日期 | 2026-10-14 | 2026-08-14 | 2026-08-14 | 2026-06-15 | 2026-03-30 | 2025-11-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 3327.46 | 3327.46 | 2807.96 | 2800.98 | 2799.68 | 2798.40 |
| 普通股本 | 3327.46 | 3327.46 | 2807.96 | 2800.98 | 2799.68 | 2798.40 |
| 优先股 | 955.54 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-09-28 | 2026-08-10 | 2026-06-30 | 2026-06-01 | 2025-12-31 | 2025-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-10-14 | 3327.46 | 955.54 | 定期报告 | 2026-09-28 |
| 2026-08-14 | 3327.46 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-08-14 | 2807.96 | 未披露 |
更多>>
From March 31, 2026 to June 30, 2026
Issuance of common stock for vested restricted stock units
Issuance of common stock pursuant to Employee Stock Purchase Plan
|
2026-06-30 |
| 2026-06-15 | 2800.98 | 未披露 | 定期报告 | 2026-06-01 |
| 2026-03-30 | 2799.68 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs of $0.4 million
Issuance of common stock through ATM line, net of commissions and issuance costs of $0.3 million
Issuance of common stock for vested restricted stock units
Issuance of common stock pursuant to Employee Stock Purchase Plan
|
2025-12-31 |
| 2025-11-10 | 2798.40 | 未披露 |
更多>>
From June 30,2025 to September 30,2025
Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs of $04 million
Issuance of common stock through ATM line net of commissions and issuance costs of less than $01 million
|
2025-09-30 |
| 2025-09-19 | 2792.40 | 未披露 |
更多>>
Common Stock offered 11,670,707 shares by the company
|
2025-09-22 |
| 2025-08-13 | 1625.33 | 未披露 | 定期报告 | 2025-08-11 |
| 2025-08-13 | 1621.92 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock pursuant to Employee Stock Purchase Plan
Issuance of common stock for vested restricted stock units
Issuance of common stock through ATM line net of commissions and issuance costs of $0.3 million
|
2025-06-30 |
| 2025-02-28 | 1502.21 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $3.3 million
Issuance of common stock pursuant to Employee Stock Purchase Plan
Issuance of common stock upon exercise of stock options
Forfeiture of shares subject to earnout
|
2024-12-31 |
| 2024-11-07 | 1500.14 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Cancellation of earnout shares
Issuance of common stock upon exercise of stock options
|
2024-09-30 |
| 2024-08-13 | 1510.53 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock pursuant to Employee Stock Purchase Plan
Issuance of common stock upon exercise of stock options
|
2024-06-30 |
| 2024-05-14 | 1508.56 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock through underwritten offering, net of discounts and commissions and offering expenses of $3.3 million
Issuance of common stock upon exercise of stock options
|
2024-03-31 |
| 2024-03-05 | 1506.39 | 未披露 | 定期报告 | 2024-02-26 |
| 2024-02-07 | 1510.00 | 未披露 |
更多>>
Common stock offered 3,900,000 shares by the company
|
2024-02-08 |
| 2024-01-02 | 1120.00 | 未披露 |
更多>>
Jasper Therapeutics, Inc. announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding voting common stock that will become effective at 12:01 a.m. Eastern Time on Thursday, January 4, 2024.
|
2024-01-04 |
| 2023-11-09 | 11157.53 | 未披露 | 定期报告 | 2023-10-31 |
| 2023-11-09 | 11085.04 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock upon exercise of stock options
|
2023-09-30 |
| 2023-08-11 | 11080.04 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock upon exercise of stock options
Issuance of common stock pursuant to Employee Stock Purchase Plan
Settlement of restricted stock units
Shares withheld for taxes
|
2023-06-30 |
| 2023-05-12 | 11032.62 | 未披露 | 定期报告 | 2023-05-01 |
| 2023-04-21 | 11028.34 | 未披露 | 定期报告 | 2023-04-14 |
| 2023-05-12 | 10942.82 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Issuance of common stock upon exercise of stock options
Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $6.6 million
Issuance of common stock through ATM offering, net of commissions and offering costs of $0.1 million
RSU settlements
|
2023-03-31 |
| 2023-03-08 | 10938.32 | 未披露 | 定期报告 | 2023-02-28 |
| 2023-01-25 | 10032.19 | 未披露 |
更多>>
Common Stock offered 60,000,000 shares by the company
|
2023-01-27 |
| 2023-01-25 | 4032.19 | 未披露 | 定期报告 | 2023-01-20 |
| 2023-03-08 | 3804.57 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to Employee Stock Purchase Plan
RSU settlements
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of common stock warrants
|
2022-12-31 |
| 2022-11-10 | 3798.44 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of stock options
RSU settlements
|
2022-09-30 |
| 2022-08-12 | 3798.32 | 未披露 | 定期报告 | 2022-08-01 |
| 2022-08-12 | 3798.13 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock upon exercise of stock options
RSU settlements
|
2022-06-30 |
| 2022-05-12 | 3787.63 | 未披露 | 定期报告 | 2022-05-09 |
| 2022-04-29 | 3787.59 | 未披露 | 定期报告 | 2022-04-26 |
| 2022-04-29 | 3787.56 | 未披露 | 定期报告 | 2022-04-11 |
| 2022-05-12 | 3787.42 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of common stock warrants
|
2022-03-31 |
| 2022-03-22 | 3787.40 | 未披露 | 定期报告 | 2022-03-21 |
| 2022-03-18 | 3787.36 | 未披露 | 定期报告 | 2022-03-10 |
| 2022-03-18 | 3785.51 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of Series A-1 redeemable convertible preferred stock for cash
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of common stock warrants
Settlement of the redeemable convertible preferred stock tranche liability
Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization
Issuance of common stock upon the Reverse Recapitalization and PIPE Financing, net of issuance costs
|
2021-12-31 |
| 2021-11-12 | 3785.32 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-11-12 | 3781.63 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization
Issuance of common stock upon exercise of stock options
Issuance of common stock upon the Reverse Recapitalization and PIPE Financing, net of issuance costs
|
2021-09-30 |
| 2021-08-26 | 4715.76 | 未披露 | 定期报告 | 2021-09-27 |
| 2021-10-18 | 3652.03 | 未披露 | 定期报告 | 2021-09-24 |
| 2020-05-13 | 1250.00 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Change in common stock subject to possible redemption
Forfeiture of Founder Shares
|
2020-03-31 |
| 2020-01-10 | 1250.00 | 未披露 |
更多>>
1.Securities offered 10,000,000 units
|
2020-01-10 |
| 2020-03-26 | 1287.50 | 未披露 |
更多>>
From August 13, 2019 to December 31, 2019
Sale of 10,000,000 Units, net of underwriting discount and offering expenses
Common stock subject to possible redemption
Issuance of Class B common stock to Sponsor
|
2019-12-31 |
From March 31, 2026 to June 30, 2026
Issuance of common stock for vested restricted stock units
Issuance of common stock pursuant to Employee Stock Purchase Plan
From December 31, 2024 to December 31, 2025
Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs of $0.4 million
Issuance of common stock through ATM line, net of commissions and issuance costs of $0.3 million
Issuance of common stock for vested restricted stock units
Issuance of common stock pursuant to Employee Stock Purchase Plan
From June 30,2025 to September 30,2025
Issuance of common stock and pre-funded warrants through underwritten offering, net of issuance costs of $04 million
Issuance of common stock through ATM line net of commissions and issuance costs of less than $01 million
Common Stock offered 11,670,707 shares by the company
From March 31, 2025 to June 30, 2025
Issuance of common stock pursuant to Employee Stock Purchase Plan
Issuance of common stock for vested restricted stock units
Issuance of common stock through ATM line net of commissions and issuance costs of $0.3 million
From December 31, 2023 to December 31, 2024
Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $3.3 million
Issuance of common stock pursuant to Employee Stock Purchase Plan
Issuance of common stock upon exercise of stock options
Forfeiture of shares subject to earnout
From June 30, 2024 to September 30, 2024
Cancellation of earnout shares
Issuance of common stock upon exercise of stock options
From March 31, 2024 to June 30, 2024
Issuance of common stock pursuant to Employee Stock Purchase Plan
Issuance of common stock upon exercise of stock options
From December 31, 2023 to March 31, 2024
Issuance of common stock through underwritten offering, net of discounts and commissions and offering expenses of $3.3 million
Issuance of common stock upon exercise of stock options
Common stock offered 3,900,000 shares by the company
Jasper Therapeutics, Inc. announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding voting common stock that will become effective at 12:01 a.m. Eastern Time on Thursday, January 4, 2024.
From June 30, 2023 to September 30, 2023
Issuance of common stock upon exercise of stock options
From March 31, 2023 to June 30, 2023
Issuance of common stock upon exercise of stock options
Issuance of common stock pursuant to Employee Stock Purchase Plan
Settlement of restricted stock units
Shares withheld for taxes
From January 1, 2023 to March 31, 2023
Issuance of common stock upon exercise of stock options
Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $6.6 million
Issuance of common stock through ATM offering, net of commissions and offering costs of $0.1 million
RSU settlements
Common Stock offered 60,000,000 shares by the company
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to Employee Stock Purchase Plan
RSU settlements
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of common stock warrants
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of stock options
RSU settlements
From March 31, 2022 to June 30, 2022
Issuance of common stock upon exercise of stock options
RSU settlements
From January 1, 2022 to March 31, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of common stock warrants
From December 31, 2020 to December 31, 2021
Issuance of Series A-1 redeemable convertible preferred stock for cash
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of common stock warrants
Settlement of the redeemable convertible preferred stock tranche liability
Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization
Issuance of common stock upon the Reverse Recapitalization and PIPE Financing, net of issuance costs
From June 30, 2021 to September 30, 2021
Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization
Issuance of common stock upon exercise of stock options
Issuance of common stock upon the Reverse Recapitalization and PIPE Financing, net of issuance costs
From January 1, 2020 to March 31, 2020
Change in common stock subject to possible redemption
Forfeiture of Founder Shares
1.Securities offered 10,000,000 units
From August 13, 2019 to December 31, 2019
Sale of 10,000,000 Units, net of underwriting discount and offering expenses
Common stock subject to possible redemption
Issuance of Class B common stock to Sponsor